Marie-Claude Gingras, PhD
The Cancer Research Program (CRP) benefits from new state-of-the-art facilities to conduct basic research at the Centre for Translational Biology (CTB), clinical cancer research at the Centre for Innovative Medicine (CIM), and evaluative cancer research at the Centre for Outcomes Research and Evaluation (CORE). Activities are supported by several newly enhanced technology platforms at the Glen site, including the Immunophenotyping, Histopathology, Biobank, Proteomics, Microscopy, Molecular Imaging, Small Animal Imaging Labs and Drug Discovery platforms.
The integration of basic, clinical and evaluative science has resulted in a new program that is able to pursue precision care research in collaboration with the Cedars Cancer Centre of the MUHC at the Glen. The CRP focuses on the mechanisms of etiology (hereditary predisposition), spread (metastasis) and progression of disease, with current studies in such domains as the identification of new markers and therapeutic targets, gene therapy, tumour suppressor genes, angiogenesis and radiosensitivity.
Discover some of our research highlights and publications on the CRP page of the 2020 RI-MUHC Annual Report
Researchers in the Cancer Research Program are involved in a multitude of research initiatives, including:
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,200 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.